KR870000843B1 - 피리딘 가용성 추출물의 제조방법 - Google Patents

피리딘 가용성 추출물의 제조방법 Download PDF

Info

Publication number
KR870000843B1
KR870000843B1 KR1019840005821A KR840005821A KR870000843B1 KR 870000843 B1 KR870000843 B1 KR 870000843B1 KR 1019840005821 A KR1019840005821 A KR 1019840005821A KR 840005821 A KR840005821 A KR 840005821A KR 870000843 B1 KR870000843 B1 KR 870000843B1
Authority
KR
South Korea
Prior art keywords
pyridine
extract
endotoxin
methanol
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019840005821A
Other languages
English (en)
Korean (ko)
Other versions
KR850002404A (ko
Inventor
레오나드 칸트렐 죤
Original Assignee
리비 이뮤노켐 리서어치 인코오퍼레이션
닐스 에이·리비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리비 이뮤노켐 리서어치 인코오퍼레이션, 닐스 에이·리비 filed Critical 리비 이뮤노켐 리서어치 인코오퍼레이션
Publication of KR850002404A publication Critical patent/KR850002404A/ko
Application granted granted Critical
Publication of KR870000843B1 publication Critical patent/KR870000843B1/ko
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1019840005821A 1983-09-23 1984-09-22 피리딘 가용성 추출물의 제조방법 Expired KR870000843B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US535037 1983-09-23
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use
US535,037 1983-09-23

Publications (2)

Publication Number Publication Date
KR850002404A KR850002404A (ko) 1985-05-13
KR870000843B1 true KR870000843B1 (ko) 1987-04-25

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005821A Expired KR870000843B1 (ko) 1983-09-23 1984-09-22 피리딘 가용성 추출물의 제조방법

Country Status (23)

Country Link
US (1) US4663306A (enExample)
JP (1) JPS60120817A (enExample)
KR (1) KR870000843B1 (enExample)
AT (1) AT385659B (enExample)
AU (1) AU566234B2 (enExample)
BE (1) BE900650A (enExample)
CA (1) CA1244765A (enExample)
CH (1) CH664897A5 (enExample)
DE (1) DE3434766C2 (enExample)
DK (1) DK446684A (enExample)
ES (1) ES8608872A1 (enExample)
FI (1) FI843716A7 (enExample)
FR (1) FR2552326B1 (enExample)
GB (1) GB2149301B (enExample)
HU (1) HU192585B (enExample)
IL (1) IL73034A (enExample)
IN (1) IN157240B (enExample)
IT (1) IT1179444B (enExample)
NL (1) NL8402902A (enExample)
NO (1) NO843776L (enExample)
NZ (1) NZ209635A (enExample)
SE (1) SE8404707L (enExample)
ZA (1) ZA847405B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
EP0714305B1 (en) * 1993-08-27 2001-12-19 Vetrepharm, Inc. Composition and method for stimulation of reproductive performance
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
CA2337445A1 (en) * 1998-07-16 2000-01-27 Sumitomo Pharmaceuticals Co., Ltd. Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
SI21171A (sl) * 2000-07-11 2003-10-31 Bayer Aktiengesellschaft Uporaba sevov parapoksvirusa ovis proti fibrozi organov
US20050106155A1 (en) * 2002-03-05 2005-05-19 Tadao Ohno Solidified tissue immuoadjuvant
JP4726485B2 (ja) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 細菌細胞壁骨格成分製剤
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
AU2003261624A1 (en) * 2003-09-05 2005-03-29 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3158054B1 (en) 2014-06-17 2025-02-19 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
CN116761582A (zh) 2020-06-23 2023-09-15 皇冠实验室有限公司 益生菌皮肤制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2269962B1 (enExample) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
ATA302384A (de) 1987-10-15
GB2149301A (en) 1985-06-12
AU566234B2 (en) 1987-10-15
ES536167A0 (es) 1986-07-16
HU192585B (en) 1987-06-29
AT385659B (de) 1988-05-10
NL8402902A (nl) 1985-04-16
FI843716L (fi) 1985-03-24
JPS60120817A (ja) 1985-06-28
ES8608872A1 (es) 1986-07-16
DE3434766A1 (de) 1986-04-30
DE3434766C2 (de) 1987-05-14
FR2552326A1 (fr) 1985-03-29
AU3340084A (en) 1985-03-28
IL73034A (en) 1988-11-15
NO843776L (no) 1985-03-25
HUT35521A (en) 1985-07-29
FR2552326B1 (fr) 1988-05-13
CA1244765A (en) 1988-11-15
IT8448894A0 (it) 1984-09-24
NZ209635A (en) 1989-01-27
DK446684D0 (da) 1984-09-19
SE8404707D0 (sv) 1984-09-20
IN157240B (enExample) 1986-02-15
BE900650A (fr) 1985-03-21
GB8423993D0 (en) 1984-10-31
FI843716A0 (fi) 1984-09-21
KR850002404A (ko) 1985-05-13
CH664897A5 (de) 1988-04-15
DK446684A (da) 1985-03-24
GB2149301B (en) 1988-06-22
JPS6254775B2 (enExample) 1987-11-17
FI843716A7 (fi) 1985-03-24
US4663306A (en) 1987-05-05
IT1179444B (it) 1987-09-16
SE8404707L (sv) 1985-03-24
ZA847405B (en) 1985-05-29

Similar Documents

Publication Publication Date Title
KR870000843B1 (ko) 피리딘 가용성 추출물의 제조방법
KR870000842B1 (ko) 정제 해독된 내독소 및 그의 제조방법
US4436728A (en) Refined detoxified endotoxin product
US4435386A (en) Refined detoxified endotoxin product
US4877611A (en) Vaccine containing tumor antigens and adjuvants
US4505900A (en) Refined detoxified endotoxin product
US4505899A (en) Refined detoxified endotoxin product
JPH0556326B2 (enExample)
US4613504A (en) Pyridine-soluble extracts of microorganisms
JPS6254774B2 (enExample)
JPH01172343A (ja) 神経内分泌系の生理的調節、免疫賦活及びホルモン依存性腫瘍の増殖抑制用医薬製剤及び該医薬製剤の製造方法